A unique maternal and placental galectin signature upon SARS-CoV-2 infection suggests galectin-1 as a key alarmin at the maternal-fetal interface.
COVID-19
PSG1
SARS-CoV-2
galectin-1
galectin-3
galectin-7
galectin-9
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
03
2023
accepted:
06
06
2023
medline:
24
7
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic imposed a risk of infection and disease in pregnant women and neonates. Successful pregnancy requires a fine-tuned regulation of the maternal immune system to accommodate the growing fetus and to protect the mother from infection. Galectins, a family of β-galactoside-binding proteins, modulate immune and inflammatory processes and have been recognized as critical factors in reproductive orchestration, including maternal immune adaptation in pregnancy. Pregnancy-specific glycoprotein 1 (PSG1) is a recently identified gal-1 ligand at the maternal-fetal interface, which may facilitate a successful pregnancy. Several studies suggest that galectins are involved in the immune response in SARS-CoV-2-infected patients. However, the galectins and PSG1 signature upon SARS-CoV-2 infection and vaccination during pregnancy remain unclear. In the present study, we examined the maternal circulating levels of galectins (gal-1, gal-3, gal-7, and gal-9) and PSG1 in pregnant women infected with SARS-CoV-2 before vaccination or uninfected women who were vaccinated against SARS-CoV-2 and correlated their expression with different pregnancy parameters. SARS-CoV-2 infection or vaccination during pregnancy provoked an increase in maternal gal-1 circulating levels. On the other hand, levels of PSG1 were only augmented upon SARS-CoV-2 infection. A healthy pregnancy is associated with a positive correlation between gal-1 concentrations and gal-3 or gal-9; however, no correlation was observed between these lectins during SARS-CoV-2 infection. Transcriptome analysis of the placenta showed that gal-1, gal-3, and several PSG and glycoenzymes responsible for the synthesis of gal-1-binding glycotopes (such as linkage-specific N-acetyl-glucosaminyltransferases (MGATs)) are upregulated in pregnant women infected with SARS-CoV-2. Collectively, our findings identify a dynamically regulated "galectin-specific signature" that accompanies the SARS-CoV-2 infection and vaccination in pregnancy, and they highlight a potentially significant role for gal-1 as a key pregnancy protective alarmin during virus infection.
Identifiants
pubmed: 37475853
doi: 10.3389/fimmu.2023.1196395
pmc: PMC10354452
doi:
Substances chimiques
1-nitrohydroxyphenyl-N-benzoylalanine
59921-69-6
Alarmins
0
Galectin 1
0
Galectins
0
LGALS1 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1196395Subventions
Organisme : NIMH NIH HHS
ID : K23 MH118999
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI156058
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI157488
Pays : United States
Informations de copyright
Copyright © 2023 Zhao, Tallarek, Wang, Xie, Diemert, Lu-Culligan, Vijayakumar, Kittmann, Urbschat, Bayo, Arck, Farhadian, Dveksler, Garcia and Blois.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2022 Jan 18;13(1):320
pubmed: 35042863
JAMA. 2021 Jun 15;325(23):2370-2380
pubmed: 33983379
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Reproduction. 2022 Feb 01;163(2):R11-R23
pubmed: 35007205
Mucosal Immunol. 2014 Mar;7(2):348-58
pubmed: 23945545
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
Clin Lab. 2022 Dec 1;68(12):
pubmed: 36546745
Am J Obstet Gynecol MFM. 2022 Jan;4(1):100492
pubmed: 34547533
Physiol Rev. 2021 Jan 1;101(1):303-318
pubmed: 32969772
Immunity. 2018 Sep 18;49(3):397-412
pubmed: 30231982
Viruses. 2022 Feb 02;14(2):
pubmed: 35215900
JAMA. 2022 Feb 22;327(8):748-759
pubmed: 35129581
J Immunol. 2017 Dec 1;199(11):3721-3730
pubmed: 29158348
Immunol Rev. 2009 Jul;230(1):232-46
pubmed: 19594640
Med. 2021 May 14;2(5):591-610.e10
pubmed: 33969332
Clin Infect Dis. 2020 Nov 19;71(16):2035-2041
pubmed: 32249918
Front Immunol. 2019 May 29;10:1166
pubmed: 31231368
J Clin Invest. 2018 Oct 1;128(10):4224-4235
pubmed: 30272581
Sci Rep. 2021 Mar 18;11(1):6357
pubmed: 33737684
Am J Reprod Immunol. 2020 Dec;84(6):e13311
pubmed: 32691950
Front Immunol. 2020 Oct 07;11:575197
pubmed: 33133091
Immunol Rev. 2009 Jul;230(1):172-87
pubmed: 19594636
JAMA Pediatr. 2022 Mar 01;176(3):290-295
pubmed: 34932066
Am J Reprod Immunol. 2015 Mar;73(3):199-213
pubmed: 25582523
Cells. 2019 Oct 31;8(11):
pubmed: 31683744
Am J Obstet Gynecol. 2021 Aug;225(2):192-194
pubmed: 33812808
Respir Med. 2021 Oct;187:106556
pubmed: 34375925
Int J Gynaecol Obstet. 2022 Mar;156(3):436-443
pubmed: 34762739
Sci Rep. 2023 Jan 26;13(1):1460
pubmed: 36702907
Front Immunol. 2021 Dec 15;12:784473
pubmed: 34975875
Cell Mol Immunol. 2016 Jan;13(1):73-81
pubmed: 25578313
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Nat Commun. 2018 Aug 17;9(1):3287
pubmed: 30120234
JAMA. 2022 Apr 19;327(15):1469-1477
pubmed: 35323851
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18472-7
pubmed: 19011096
JMIR Pediatr Parent. 2022 Oct 4;5(4):e31579
pubmed: 35319475
Reproduction. 2020 Nov;160(5):685-694
pubmed: 33065543
Int J Gynaecol Obstet. 2022 Dec;159(3):651-661
pubmed: 35810414
BMJ. 2022 Apr 26;377:e069739
pubmed: 35473709
Nat Rev Immunol. 2017 Aug;17(8):469-482
pubmed: 28627518
Cell. 2014 Feb 13;156(4):744-58
pubmed: 24529377
Obstet Gynecol. 2021 Aug 1;138(2):278-280
pubmed: 33910219
J Biol Chem. 2015 Feb 13;290(7):4422-31
pubmed: 25548275
Glycobiology. 2020 Oct 21;30(11):895-909
pubmed: 32280962
Sci Transl Med. 2021 Oct 27;13(617):eabi8631
pubmed: 34664972
Mol Hum Reprod. 2013 Jan;19(1):43-53
pubmed: 23002109
Jpn J Infect Dis. 2021 Nov 22;74(6):530-536
pubmed: 33790073
mBio. 2021 May 4;12(3):
pubmed: 33947753
Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149
pubmed: 35972987
Reproduction. 2020 Nov;160(5):737-750
pubmed: 33065549
Vaccine. 2021 Oct 1;39(41):6037-6040
pubmed: 34531079
Sci Rep. 2022 Jan 24;12(1):1272
pubmed: 35075140
PLoS One. 2014 Mar 20;9(3):e92371
pubmed: 24651720
Front Microbiol. 2022 Jul 13;13:923546
pubmed: 35910606
Nat Rev Immunol. 2022 May;22(5):277-282
pubmed: 35304596
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34014840
Cytokine. 2022 Jun;154:155894
pubmed: 35490452
PLoS One. 2013;8(2):e57491
pubmed: 23469002
Ultrasound Obstet Gynecol. 2022 Aug;60(2):234-242
pubmed: 35502537
AJOG Glob Rep. 2022 Feb;2(1):100049
pubmed: 35005663
Front Immunol. 2022 Oct 17;13:1011185
pubmed: 36325323
Nat Immunol. 2007 Aug;8(8):825-34
pubmed: 17589510
Mol Cancer Res. 2018 Jun;16(6):1024-1034
pubmed: 29549127
Mol Immunol. 2018 Sep;101:80-85
pubmed: 29890367
Clin Infect Dis. 2022 Aug 24;75(1):e603-e610
pubmed: 35171998
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Ultrasound Obstet Gynecol. 2021 Sep;58(3):450-456
pubmed: 34198360
Cell Death Dis. 2020 Jul 23;11(7):560
pubmed: 32703931
Clin Med (Lond). 2021 Sep;21(5):e446-e450
pubmed: 34507928